Eli Lilly Acquires AtaiBeckley for $3.8B | Business and Finance News

Eli Lilly just dropped a blockbuster $2.8 billion deal to acquire AtaiBeckley, a psychedelic-focused mental health startup, with potential to hit $3.8 billion if drug candidates succeed. The acquisition, expected to close in Q3, bolsters Lilly’s neuroscience arsenal and follows a wave of strategic buys—including vaccine and cancer firms—highlighting its pivot toward next-gen therapies and blockbuster growth. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/a9cdc50b9ed59d72